Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2000 1
2003 2
2004 3
2005 2
2006 1
2007 8
2008 3
2009 6
2010 8
2011 16
2012 22
2013 20
2014 22
2015 21
2016 19
2017 17
2018 21
2019 29
2020 25
2021 18
2022 26
2023 19
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

290 results

Results by year

Filters applied: . Clear all
Page 1
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.
Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, Pais P, López-Jaramillo P, Leiter LA, Dans A, Avezum A, Piegas LS, Parkhomenko A, Keltai K, Keltai M, Sliwa K, Peters RJ, Held C, Chazova I, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Sanchez-Vallejo G, McKelvie R, Pogue J, Jung H, Gao P, Diaz R, Lonn E; HOPE-3 Investigators. Yusuf S, et al. N Engl J Med. 2016 May 26;374(21):2021-31. doi: 10.1056/NEJMoa1600176. Epub 2016 Apr 2. N Engl J Med. 2016. PMID: 27040132 Free article. Clinical Trial.
In the rosuvastatin group, there was no excess of diabetes or cancers, but there was an excess of cataract surgery (in 3.8% of the participants, vs. 3.1% in the placebo group; P=0.02) and muscle symptoms (in 5.8% of the participants, vs. 4.7% in the placebo group; P=0.005) …
In the rosuvastatin group, there was no excess of diabetes or cancers, but there was an excess of cataract surgery (in 3.8% of the pa …
The Lucerne Toolbox 2 to optimise axillary management for early breast cancer: a multidisciplinary expert consensus.
Kaidar-Person O, Pfob A, Gentilini OD, Borisch B, Bosch A, Cardoso MJ, Curigliano G, De Boniface J, Denkert C, Hauser N, Heil J, Knauer M, Kühn T, Lee HB, Loibl S, Mannhart M, Meattini I, Montagna G, Pinker K, Poulakaki F, Rubio IT, Sager P, Steyerova P, Tausch C, Tramm T, Vrancken Peeters MJ, Wyld L, Yu JH, Weber WP, Poortmans P, Dubsky P. Kaidar-Person O, et al. Among authors: yu jh. EClinicalMedicine. 2023 Jul 14;61:102085. doi: 10.1016/j.eclinm.2023.102085. eCollection 2023 Jul. EClinicalMedicine. 2023. PMID: 37528842 Free PMC article. Review.
A Life-Threatening Bronchogenic Cyst.
Han SJ, Cho HJ, Kang MW, Yu JH, Na MH, Kang SK. Han SJ, et al. Among authors: yu jh. Korean J Thorac Cardiovasc Surg. 2018 Feb;51(1):69-71. doi: 10.5090/kjtcs.2018.51.1.69. Epub 2018 Feb 5. Korean J Thorac Cardiovasc Surg. 2018. PMID: 29430433 Free PMC article.
Development of a deep pathomics score for predicting hepatocellular carcinoma recurrence after liver transplantation.
Qu WF, Tian MX, Lu HW, Zhou YF, Liu WR, Tang Z, Yao Z, Huang R, Zhu GQ, Jiang XF, Tao CY, Fang Y, Gao J, Wu XL, Chen JF, Zhao QF, Yang R, Chu TH, Zhou J, Fan J, Yu JH, Shi YH. Qu WF, et al. Among authors: yu jh. Hepatol Int. 2023 Aug;17(4):927-941. doi: 10.1007/s12072-023-10511-2. Epub 2023 Apr 8. Hepatol Int. 2023. PMID: 37031334 Free PMC article.
[Trans-fatty acids and cardiovascular diseases].
Su H, Yu JH. Su H, et al. Among authors: yu jh. Zhonghua Xin Xue Guan Bing Za Zhi. 2007 Jun;35(6):586-8. Zhonghua Xin Xue Guan Bing Za Zhi. 2007. PMID: 17711729 Review. Chinese. No abstract available.
Quincke's Sign of Janeway Lesion in Infective Endocarditis.
Cho HJ, Yu JH. Cho HJ, et al. Among authors: yu jh. Am J Respir Crit Care Med. 2022 May 15;205(10):e51-e52. doi: 10.1164/rccm.202110-2362IM. Am J Respir Crit Care Med. 2022. PMID: 35085054 No abstract available.
290 results